Literature DB >> 7273486

Immunologic enhancement of collagen accumulation in progressive systemic sclerosis (PSS).

M K Cathcart, R S Krakauer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7273486     DOI： 10.1016/0090-1229(81)90201-4

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN： 0090-1229


× No keyword cloud information.
  7 in total

Review 1.  T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples.

Authors:  C Chizzolini
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Origin of the enhanced activity of lysosomal beta-galactosidase in serum and skin in progressive systemic sclerosis.

Authors:  K Herrmann; E Schulze; U F Haustein; H J Böhme; V Ziegler
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

3.  Replication and phenotypic expression of control and scleroderma human fibroblasts: responses to growth factors.

Authors:  E C LeRoy; S Mercurio; G K Sherer
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

4.  Lymphocyte subpopulations in peripheral blood and bone marrow in patients with idiopathic myelofibrosis.

Authors:  E Vellenga; S Poppema; C G Kallenberg; M R Halie
Journal:  Blut       Date:  1987-08

5.  In vitro correction of a deficiency of Con A-induced suppressor cell function in primary biliary cirrhosis by a pharmacological concentration of colchicine.

Authors:  D Ilfeld; E Theodor; G Delpre; O Kuperman
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

6.  Animal model of human disease. Avian scleroderma. An inherited fibrotic disease of white Leghorn chickens resembling progressive systemic sclerosis.

Authors:  J van de Water; M E Gershwin
Journal:  Am J Pathol       Date:  1985-09       Impact factor: 4.307

7.  Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons.

Authors:  M R Duncan; B Berman
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.